Hartmut Michel
Former positions of Hartmut Michel
| Companies | Position | End |
|---|---|---|
elbion AG
 elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | Director/Board Member | 21/06/2007 |
Experiences
Positions held
Linked companies
| Private companies | 1 |
|---|---|
elbion AG
elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | Commercial Services |
- Stock Market
- Insiders
- Hartmut Michel
